...
首页> 外文期刊>Clinical and applied thrombosis/hemostasis >Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels in Patients with Essential Hypertension.
【24h】

Effect of Antihypertensive Treatment on Plasma Fibrinogen and Serum HDL Levels in Patients with Essential Hypertension.

机译:降压治疗对原发性高血压患者血浆纤维蛋白原和血清HDL水平的影响。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

SUMMARY: The influence of hypertension, and its treatment, on circulating lipid and fibrinogen (Fib) concentrations in patients with essential hypertension was investigated. The lipid profile and Fib levels were measured in 353 patients (131 men) with essential hypertension. Their median age was 60 years (range: 18-85 years). All patients had normal results from liver, renal, and thyroid function tests. There were 162 patients (45.9%) who were not receiving antihypertensive treatment. Of the remaining patients, 117 were taking `lipid-hostile' beta-blockers, thiazide diuretics) antihypertensives and 74 were taking `lipid-neutral' (angiotensin-converting enzyme inhibitors, calcium channel blockers, angiotensin-II receptor blockers) agents. Patients who were taking `lipid-hostile' antihypertensive drugs had significantly higher plasma Fib concentrations when compared with those taking `lipid-neutral' antihypertensives or those not receiving antihypertensive treatment. These differences were not attributable to established factors that influence plasma Fib levels, since when smokers and patients with diabetes mellitus and/or vascular disease were excluded, the difference remained significant. In addition, in these more homogeneous groups, patients receiving `lipid-neutral' treatment had significantly higher serum high-density lipoprotein (HDL) cholesterol levels when compared with both those taking `lipid-hostile' antihypertensives and untreated ones. There were no significant differences in the other lipid variables, independently of the presence/absence or the type of antihypertensives. These results suggest that antihypertensive drugs have additional effects, beyond lowering blood pressure, on other vascular risk factors, like Fib and HDL. These effects may depend on the type of drug used.
机译:摘要:研究了高血压及其治疗对原发性高血压患者循环脂质和纤维蛋白原(Fib)浓度的影响。测定了353名原发性高血压患者(131名男性)的血脂谱和Fib水平。他们的中位年龄为60岁(范围:18-85岁)。所有患者的肝,肾和甲状腺功能检查均正常。有162例(45.9%)未接受降压治疗。在其余的患者中,有117名正在服用“脂质敌对性”β受体阻滞剂,噻嗪类利尿剂)和74名正在服用“脂质中性”(血管紧张素转换酶抑制剂,钙通道阻滞剂,血管紧张素II受体阻滞剂)药物。与服用“脂中性”降压药或未接受降压药的患者相比,服用“脂敌对”降压药的患者血浆Fib浓度明显更高。这些差异并非归因于影响血浆Fib水平的既定因素,因为当排除吸烟者和患有糖尿病和/或血管疾病的患者时,差异仍然很明显。此外,在这些均质性较高的人群中,接受“脂质中性”治疗的患者与服用“脂质敌对性”抗高血压药的患者和未经治疗的患者相比,血清高密度脂蛋白(HDL)胆固醇水平明显更高。其他脂质变量无明显差异,与是否存在降压药或降压药的类型无关。这些结果表明,降压药除降低血压外,还对其他血管危险因子(如Fib和HDL)具有附加作用。这些影响可能取决于所用药物的类型。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号